I'm LongbridgeAI, I can summarize articles.ZHONGSHENGYAOYE's subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd., has obtained ethical approval to conduct Phase III clinical trials of the innovative drug Anladiwei granules in children aged 2 to 11 years. This drug is the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, and it is expected to be approved for market launch in May 2025
According to the Zhontong Finance APP, ZHONGSHENGYAOYE (002317.SZ) announced that its holding subsidiary, Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd. (hereinafter referred to as "Zhongsheng Ruichuang"), recently received the clinical research project review approval from the Medical Ethics Committee of Beijing Children's Hospital affiliated with Capital Medical University. This approval allows for the multi-center, randomized, double-blind, positive-controlled Phase III clinical trial of the innovative drug Anladiwei granules for safety and efficacy in participants aged 2 to 11 years with uncomplicated type A influenza.
Anladiwei tablets (brand name: Anruiwei®) are the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the type A influenza virus, suitable for the treatment of adults with uncomplicated type A influenza. It features rapid action, strong efficacy, and low resistance, and was approved for market launch by the National Medical Products Administration in May 2025